Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes.

MLA

Foster, Timothy P., et al. “Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes.” Diabetes Care, vol. 47, no. 2, Feb. 2024, pp. 285–89. EBSCOhost, https://doi.org/10.2337/dc23-1750.

APA

Foster, T. P., Jacobsen, L. M., Bruggeman, B., Salmon, C., Hosford, J., Chen, A., Cintron, M., Mathews, C. E., Wasserfall, C., Brusko, M. A., Brusko, T. M., Atkinson, M. A., Schatz, D. A., & Haller, M. J. (2024). Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes. Diabetes Care, 47(2), 285–289. https://doi.org/10.2337/dc23-1750

Chicago

Foster, Timothy P., Laura M. Jacobsen, Brittany Bruggeman, Chelsea Salmon, Jennifer Hosford, Angela Chen, Miriam Cintron, et al. 2024. “Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes.” Diabetes Care 47 (2): 285–89. doi:10.2337/dc23-1750.